**Abstract**

Small non-coding microRNA (miRNA) coordinate mRNA translation in the brain, and their dysregulation has significant consequences in neurodevelopmental disorders. This hypothesis is supported by strong genetic evidence at the genome-wide associated variant in MIR137 (rs1625579) in recent PGC mega analysis of schizophrenia. We used a TaqMan genotyping and expression strategy to investigate the allelic expression (rs2660304) in postmortem DLPFC from subjects with schizophrenia and controls with no history of psychiatric disorder (n=74). While no significant difference was observed in the expression of miR-137 in postmortem DLPFC between the controls and schizophrenia, we found that mature miR-137 expression was significantly reduced in the samples homozygous for the risk allele compared to those homozygous for the alternative. Expression in the heterozygotes was not significantly different to either of the homozygotes, however, when we examined the allelic imbalance by differentiating pri-miR-137 expression at each allele (rs2660304), the risk allele was significantly lower compared to the alternative. Functional consequences of dysregulated miR-137 in neurons was then examined human SH-SY5Y neuroblasts electroporated synthetic miR-137 and its antisense antagonist using gene expression profiling. While over expression of miR-137 produced relatively few changes in target gene expression the repression of miR-137 in these cells produced changes in a large number of target genes, many of which have also been associated with schizophrenia. These genes were also enriched in several pathways believed to be involved in the neuropathology of the disorder including, axon guidance, glucocorticoid receptor signalling, ErbB signalling, dopamine-DARPP32 feedback in cAMP signalling, and mTOR signalling. This suggests that the risk variant in MIR137 is an eQTL and results in haploinsuficiency in carriers causing dysfunction in several pathways relevant to schizophrenia.
